长效干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其对静息能量消耗和营养状态的影响*

doi:10.3969/j.issn.1672-5069.2021.06.012

Abstract

Abstract: Objective The aim of this clinical trial was to investigate the response of peginterferon-α-2a (PEG-IFNα-2a)and ribavirin combination in treatment of patients with chronic hepatitis C and its impact on resting energy expenditure (REE) and nutritional status. Methods Forty-eight patients with CHC were enrolled in this clinical trial between April 2017 and April 2019, and were randomly divided into observation and control group, with 24 cases in each group. The patients in the observation group were treated with PEG-IFNα-2a and ribavirin, and those in the control group were treated with interferon α-2a (IFNα-2a) and ribavirin combination for 48 weeks. The REE, predicted REE (pREE) as well as body mass index (BMI) and serum prealbumin (PA) and albumin (ALB) levels were obtained. Results At the end of 48 week treatment and 6 month of followed-up, the complete response in the observation group were 62.5% and 54.2%, both significantly higher than 37.5% and 29.2% in the control (P＜0.05); at presentation, the REE and pREE in the observation were (1504.6±481.5)kcal/d and (1432.3±229.3)kcal/d, both increased to (1822.1±546.7)kcal/d and (1241.8±208.6)kcal/d at the end of the treatment, and they were (1505.2±482.1)kcal/d and (1433.5±231.2)kcal/d in the control before treatment, and they also increased to (1824.4±547.6)kcal/d and (1243.1±208.8)kcal/d at the end of the regimen, not significantly different between the two groups (P>0.05); before treatment, the BMI, serum PA and ALB levels in the observation were (19.2±2.0)kg/m², (161.5±45.2)mg/L and (38.4±4.2)g/L, they decreased to (17.1±1.5)kg/m², (135.8±40.2)mg/L and (34.2±3.2)g/L at the end of the treatment, and those in the control before treatment were (19.3±2.1)kg/m², (161.3±45.0)mg/L and (38.5±4.4)g/L, and all decreased to (17.2±1.5)kg/m², (136.3±40.2)mg/L and (34.2±3.1)g/L at the end of the treatment, without significant differences between the two groups (P>0.05). Conclusion Compared with IFNα-2a and ribavirin combination, the application of PEG-IFNα-2a and ribavirin in treatment of patients with CHC could achieve a better virological response, while no matter IFNα-2a or PEG-IFNα-2a might increase resting energy expenditure and induce malnutrition, which warrants clinical attentions.

Key words: Chronic hepatitis C, Peginterferon-α-2a, Ribavirin, Resting energy expenditure, Therapy

Jiang Hao, Zhang Wen, Chen Xia. Peginterferon-α and ribavirin combination in treatment of patients with chronic hepatitis C and its impact on resting energy expenditure and nutritional status[J]. Journal of Practical Hepatology, 2021, 24(6): 815-818.

References

[1] Collier J D, Adams P A, Feinman V, et al. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology, 2016, 15(6):1013-1016.
[2] Schaefer M, Heinz A, Backmund M . Treatment of chronic hepatitis c in patients with drug dependence: time to change the rules? Addiction, 2015, 99(9):1167-1175.
[3] 姚轶男, 黄鹏, 陈红波,等. 江苏省句容市既往有偿献血人群慢性丙型肝炎重度肝纤维化影响因素研究. 中华流行病学杂志, 2017, 38(1):49-52.
[4] Yang S Y, Lee H W, Lee Y J, et al. Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis c in hemophilia in Korea. J Hepatol, 2015, 21(2):125-130.
[5] Tahata Y, Hiramatsu N, Oze T, et al. Impact of ribavirin dosage in chronic hepatitis c patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. J Med Virol, 2016, 88(10):1776-1784.
[6] 中华医学会肝病学分会. 丙型肝炎防治指南(2015年更新版). 中华实验和临床感染病杂志(电子版), 2015, 29(5):1-19.
[7] 冯金周. 亚低温对重型颅脑损伤患者静息能量消耗影响的随机对照研究. 中华神经外科杂志, 2015, 31(31):192-195.
[8] 贾星宇, 华晨, 刘励军,等. 不同方法检测有创机械通气患者静息能量消耗及其意义. 中华内科杂志, 2018, 57(8):596-598.
[9] Mangia A, Andriulli A, Zenarola P, et al. Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis c patients. J Med Virol, 2015, 59(3):277-280.
[10] Foster G R, Irving W L, Cheung M C M, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol, 2016, 64(6):1224-1231.
[11] Lee H J, Yeon J E, Yoon E L, et al. Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years. Intervirology, 2015, 58(1):14-21.
[12] Meng Q H, Hou W, Yu H W, et al. Resting energy expenditure and substrate metabolism in patients with acute-on-chronic hepatitis B liver failure. J Clin Gastroenterol, 2011, 45(5):456-461.
[13] 李剑萍, 陈学福, 严勤,等. 索磷布韦维帕他韦联合或不联合利巴韦林治疗中国成人慢性丙型肝炎病毒感染者的疗效和安全性. 中华肝脏病杂志, 2020, 28(10):831-837.
[14] Lawitz E, Poordad F, Brainard D M, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology, 2015, 61(3):769-775.
[15] González-Peralta R P, Liu W Z, Davis G L, et al. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy. J Viral Hepatit, 2015, 4(2):99-106.
[16] Peter J, Nelson D R . Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. Liver Int, 2015, 35(1):65-70.
[17] Saleh H, Mohammad I . A bayesian approach for population pharmacokinetic modeling of pegylated interferon α-2a in hepatitis C patients. Clin Pharmacokinet, 2017, 56(11):1369-1379.
[18] Helal G K, Gad M A, Abd-Ellah M F, et al. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol, 2016, 81(12):2170-2178.
[19] Pawlotsky J M, Flisiak R, Sarin S K, et al. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology, 2015, 62(4):1013-1023.
[20] Fioravante M, Alegre S M, Marin D M, et al. Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment.. Nutrition, 2012, 28(6):630-634.

Peginterferon-α and ribavirin combination in treatment of patients with chronic hepatitis C and its impact on resting energy expenditure and nutritional status

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Feihu, Xue Jianya, Zhu Yongmei, et al. Short-term efficacy of sofosbuvir and velpatasvir in the treatment of patients with hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(6): 819-822.
[2]	Du Yunfei, Liu Jingrui, Ye Feixiang. Efficacy of N-acetylcysteine and dicyclol combination in the treatment of patients with antituberculous drugs-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(6): 847-850.
[3]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2021, 24(6): 867-870.
[4]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[5]	Wang Jing, Bi Ning, Fang Liang, et al. Efficacy of transarterial intrahepatic transplantation of autologous bone marrow stem cells in the treatment of patients with decompensated hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 887-890.
[6]	Yu Shigang, Tian Jia, Wu Tie, et al. Damage control surgery in dealing with patients with traumatic liver rupture [J]. Journal of Practical Hepatology, 2021, 24(6): 915-918.
[7]	Cai Chuang, Fan Ruoying, Li Wei, et al. Impact of periampullary diverticula on surgical efficacy of ERCP in dealing with patients with choledocholithiasis [J]. Journal of Practical Hepatology, 2021, 24(6): 919-922.
[8]	Liang Chen, Zheng Sujun. Highlights of treatments for patients with Wilson's disease [J]. Journal of Practical Hepatology, 2021, 24(6): 930-933.
[9]	Li Wei, Song Weidong, Xie Batu Baiyin. Efficacy of esophageal variceal ligation and transjugular intrahepatic portosystemic shunt in treatment of patients with liver cirrhosis and esophageal varices bleeding [J]. Journal of Practical Hepatology, 2021, 24(5): 629-632.
[10]	Ji Minyou, Li Chao, Zhao Xingzhong, et al. Intestinal flora changes in patients with hepatitis B-induced liver cirrhosis after entecavir and glycyrrhizin combination treatment [J]. Journal of Practical Hepatology, 2021, 24(5): 641-644.
[11]	Liu Gongwei, Wu Xue, Tang Dan, et al. Re-observation of splenectomy and esophagogastric devascularization in patients with hepatitis B cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2021, 24(5): 649-652.
[12]	Han Hongyan, Pan Juan, Jiang Wenping, et al. Efficacy of 3D regimen in the treatment of patients with chronic hepatitis C with genotype 1b infection [J]. Journal of Practical Hepatology, 2021, 24(5): 689-692.
[13]	Xu Xiangtao, Qiao Fei, Che Junyong, et al. Short-term efficacy of Huazhuo Tongyu decoction in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(5): 701-704.
[14]	Liu Lixia, Lin Yingyuan, Li Huamin, et al. Comparative study on the clinical efficacy of lorazepam and oxazepam in treatment of patients with alcoholic liver diseases and alcohol withdrawal syndrome [J]. Journal of Practical Hepatology, 2021, 24(5): 709-712.
[15]	Liu Hong, Wang Yao, Hu Yufeng, et al. Short-term curative efficacy of ultrasound-guided cyst puncture, laparoscopic fenestration and laparotomic fenestration drainage in patients with hepatic cysts [J]. Journal of Practical Hepatology, 2021, 24(5): 745-748.